Vosoritide's Hypochondroplasia Phase 3 Win: Regulatory Path Clear, Payer Battle Looms

BioMarin's VOXZOGO Phase 3 Data Published, sNDA Submitted for Hypochondroplasia

BioMarin Pharmaceutical Inc. announced positive results from its Phase 3 CANOPY-HCH-3 study of VOXZOGO (vosoritide) in children with hypochondroplasia. The data, published in NEJM Evidence and presented at ESPE 2026, showed statistically significant improvements in annualized growth velocity (AGV), standing height, height Z-score, and arm span after 52 weeks compared to placebo. VOXZOGO met its primary endpoint with an AGV improvement of 2.33 cm/year (p<0.0001). The safety profile was consistent with previous studies, with mostly mild adverse events. BioMarin has submitted a supplemental New Drug Application (sNDA) to the FDA and is pursuing submissions with EMA and other authorities, aiming for a potential 2027 launch as the first targeted therapy for hypochondroplasia.

• The Phase 3 CANOPY-HCH-3 study demonstrated that VOXZOGO treatment led to statistically significant improvements in multiple growth parameters in children with hypochondroplasia. After 52 weeks, patients showed a 2.33 cm/year increase in annualized growth velocity (p<0.0001), a 2.35 cm increase in standing height (p<0.0001), a 0.39 standard deviation score improvement in height Z-score (p<0.0001), and a 1.03 cm increase in arm span (p=0.0082) compared to placebo.
• The safety profile of VOXZOGO in the CANOPY-HCH-3 study was consistent with its established profile in achondroplasia, with most adverse events being mild and no treatment-related serious adverse events reported. Additionally, children receiving VOXZOGO showed numerical improvements in quality of life, and follow-up will continue to assess the impact of treatment over a longer term.
• Based on these compelling results, BioMarin has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for approval of VOXZOGO for hypochondroplasia, and is also on track with submissions to the European Medicines Agency (EMA) and other regional health authorities. If approved, VOXZOGO would be the first targeted therapy for this condition, with a potential launch in 2027.

The Burden of Hypochondroplasia and Current Treatment Gaps

Hypochondroplasia presents a significant clinical management challenge, driven by the absence of approved pharmacological therapies and the limitations of existing interventional options. The disease's wide range of clinical severity further complicates standardized treatment planning.

• No approved medications for short stature: As of the phase 2 trial of vosoritide in hypochondroplasia, there were currently no approved medications to treat short stature in children with hypochondroplasia, leaving a critical therapeutic gap for this patient population.

• Surgical limb lengthening carries substantial risk: Limb lengthening procedures — including crossed lengthening of the femur and tibia — are associated with complications such as limb length discrepancy (≥1.0 cm in five of 12 patients undergoing crossed lengthening), valgus or varus malalignment, pin site infections, fractures, equinus deformities, and premature fibular consolidation. These outcomes require careful surgical attention and, in several cases, surgical reintervention.

• Vosoritide efficacy is promising but not universally predictive: While vosoritide demonstrated a 1.81 cm/year increase in absolute annualized growth velocity and a gain of 0.36 in height standard deviation score over 12 months, drug exposure as measured by average pharmacokinetic AUC did not correlate with any growth outcome. More studies are needed to identify specific patient characteristics that can predict response to therapy and clinical outcomes.

• Lifelong, multidisciplinary management is required: Hypochondroplasia is a progressive disease requiring lifelong management through multidisciplinary collaboration, encompassing skeletal dysplasia, middle ear dysfunction, motor and language developmental delay, chronic pain, sleep apnea, obesity, and other systemic complications — underscoring the breadth of unmet need beyond linear growth alone.

• Long-term outcomes remain under investigation: The long-term impact of emerging therapies on comorbidities such as foramen magnum stenosis, spinal stenosis, and sleep apnea remains under investigation, leaving clinicians without definitive guidance on durability and systemic benefit.

CANOPY-HCH-3: Significant Growth Improvements with VOXZOGO

Two recent studies have examined vosoritide in children with hypochondroplasia. The first, a phase 2 trial titled "Vosoritide treatment for children with hypochondroplasia", enrolled 24 participants with a mean age of 5.86 years in a single-arm, open-label design at a single centre in the USA. The intervention was vosoritide administered daily via subcutaneous injection at 15 μg/kg/day, following a 6-month observation period to establish baseline annualized growth velocity. After 12 months of treatment, annualized growth velocity increased by 2.26 standard deviations and height SDS increased by 0.36 SD versus the observation period, with a 1.81 cm/year increase in absolute annualized growth velocity. Hypochondroplasia-specific height SDS increased by 0.38 SD. On the safety side, vosoritide was well tolerated with no treatment-related serious adverse events; injection site reactions occurred in 83.3% of participants, and no participants discontinued therapy due to an adverse event.

The second study, "Effect of Vosoritide therapy on IGF-I and Endogenous C-type Natriuretic Peptide in Hypochondroplasia", examined biomarker responses in pre-pubertal children with hypochondroplasia (ages 3–11 years, height <-2.25 SD) during the same single-arm, unblinded, standardized 12-month Phase II clinical trial of vosoritide at 15 μg/kg/day. The study reported that baseline IGF-1 values were reduced in children with hypochondroplasia and increased throughout the study, though IGF-1 SD did not change significantly. NTproCNP was raised at baseline and declined throughout the study, with NTproCNP SD significantly lower at Months 6 and 12 on treatment. A positive correlation was observed between the change in IGF-1 concentrations and the change in NTproCNP plasma concentrations at 12 months (Rho=0.57, p=0.024), suggesting a possible interaction between IGF-1 and CNP signaling. Changes in height SD or annualized growth velocity were not correlated to IGF-1 or NTproCNP SD at 12 months.

Leveraging VOXZOGO's Known Safety for Hypochondroplasia Approval

Across clinical trials and real-world studies, vosoritide has demonstrated a consistently favorable safety and tolerability profile. In the pivotal phase 2 dose-finding study in children aged 5 to 14 years, adverse events occurred in 35 of 35 patients (100%), with serious adverse events in 4 of 35 patients (11%), and therapy was discontinued in 6 patients, in 1 because of an adverse event. The phase 2 trial in infants and children aged 3–59 months reported adverse events in all 75 (100%) participants, at an annual rate of 204.5 adverse events per patient in the vosoritide group and 73.6 per patient in the placebo group, with most events being transient injection-site reactions and injection-site erythema. Serious adverse events in that trial occurred in three (7%) participants in the vosoritide group — decreased oxygen saturation, respiratory syncytial virus bronchiolitis and sudden infant death syndrome, and pneumonia — compared with six (19%) in the placebo group. The phase 3 extension study, encompassing 464.05 person years of exposure over up to 6 years of continuous treatment, reported no long-term harms or deaths, with vosoritide described as well tolerated throughout.

A notable safety signal specific to early infancy is the risk of hypotension and vomiting following subcutaneous injection, attributable to vosoritide's vasodilating effect. Two published case reports describe cardiovascular adverse events in infants: a one-month-old female who developed transient symptomatic hypotension accompanied by vomiting, and a three-month-old female who developed prolonged compensated shock with marked tachycardia requiring intervention, including repetitive bolus saline injection. These cases indicate the need to monitor patients for cardiovascular adverse events following subcutaneous injection of vosoritide in early infancy. A review of clinical and real-world evidence similarly identifies mild injection site reactions and transient hypotension in infants as the most common adverse effects.

Real-world data corroborate the clinical trial safety findings. In a retrospective cohort study from Portugal involving 27 children aged 2–14 years, injection site reactions were the most common adverse drug reaction observed (n = 14), no serious adverse drug reactions were reported, and there were no discontinuations due to adverse drug reactions. A systematic review and meta-analysis encompassing 696 pediatric patients across 10 studies reported uniform profiles of adverse events, mostly limited to mild injection-site related issues and no serious complications. Collectively, these data indicate that the adverse event profile of vosoritide across studied populations is predominantly characterized by mild, injection-site-related events, with cardiovascular monitoring warranted particularly in the youngest patients.

VOXZOGO's Hypochondroplasia Success: A New Growth Trajectory

The recent positive Phase 3 results for VOXZOGO in children with hypochondroplasia represent a pivotal moment for patients and for BioMarin. With statistically significant improvements in annualized growth velocity, standing height, and height Z-score, vosoritide is poised to become the first targeted therapy for this rare genetic condition. This success builds directly on the drug's established efficacy in achondroplasia, reinforcing the scientific premise that antagonizing FGFR3 signaling via a C-type natriuretic peptide analog can effectively promote bone growth across related skeletal dysplasias.

For BioMarin, this expansion into hypochondroplasia signifies a strategic broadening of VOXZOGO's market footprint. The company can leverage its existing commercial infrastructure and deep expertise in rare disease patient engagement, ensuring a streamlined and impactful launch. This move not only strengthens BioMarin's leadership in skeletal dysplasias but also validates its platform approach for addressing FGFR3-mediated disorders.

However, as with any novel therapy, critical considerations remain. Existing evidence points to a risk of transient hypotension, particularly in very young infants, which requires careful monitoring and adherence to specific administration guidelines. Furthermore, while the drug's overall efficacy is clear, studies indicate that drug exposure does not directly correlate with growth outcomes, suggesting a need for further research to identify patient-specific predictors of response. Finally, while long-term data in achondroplasia show sustained benefits, comprehensive long-term data on adult height, skeletal complications, and overall quality of life in hypochondroplasia patients will be crucial to fully understand the drug's transformative potential.